Sjögren's disease & overlap diseases
FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren’s syndrome
Authors' conclusion
FDG-PET/CT can assist in excluding pSS-associated lymphomas in patients without PET abnormalities, possibly leading to a decrease of invasive biopsies in suspected lymphoma patients. Furthermore, FDG-PET/CT is able to detect systemic manifestations in pSS and can guide to the best biopsy location.
Study context
- Population
- ACR-EULAR-positive pSS patients who underwent FDG-PET/CT
- Participants
- 70 patients
- Comparison
- FDG-PET/CT findings in pSS patients with vs without lymphoma
- Lymphoman = 26
- Outcome
- Discrimination between pSS patients with and without lymphoma by FDG-PET/CT (standardized uptake values (SUV) cut-offs)
Methodological detailsROC curve analyses
- ROC curve analyses
Performance
As reported in the abstract
Discrimination of lymphoma vs non-lymphoma in pSS by combined FDG-PET/CT findings (nodular lung lesions, parotid SUVmax > 3.1, submandibular SUVmax > 2.9)
Sensitivity, at least one of the three features present
92%
Specificity, at least two features present
91%
Optimal SUVmax cut-off, parotid gland
3.1
Optimal SUVmax cut-off, submandibular gland
2.9
Further findings
Systemic disease activity
- FDG-PET/CT detected systemic manifestations, mostly lymph nodes, entheses and lungs
Original publication
FDG-PET/CT discriminates between patients with and without lymphomas in primary Sjögren’s syndrome. Rheumatology (Oxford). Published 9 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →